Skip to main content
You are the owner of this article.
You have permission to edit this article.
Edit
A dozen lots of Chantix recalled

A dozen lots of Chantix recalled

{{featured_button_text}}
health graphic

People using Chantix to try to quit smoking should be aware of a recall of 12 lots of Chantix (Varenicline) tablets announced Monday.

Pfizer is recalling two lots of Chantix 0.5 mg tablets, two lots of Chantix 1 mg tablets and eight lots of a Chantix kit of 0.5 mg/1 mg tablets due to the presence of a nitrosamine, N-nitrosovarenicline, above the Pfizer-established Acceptable Daily Intake level, an advisory from the FDA stated.

Long-term ingestion of N-nitrosovarenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication, the bulletin stated. The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.

To date, Pfizer has not received any reports of adverse events that have been related to this recall.

Recommendations:

• Patients currently taking Chantix should consult with their doctor to confirm if they received an affected lot and, if appropriate, about alternative treatment options.

• Wholesalers and distributors with an existing inventory of the lots should stop use and distribution and quarantine the product immediately. If you have any of the affected product lots in your inventory, follow the instructions for returning the product.

• Patients with dispensed affected lots in their possession are requested to return product and follow instructions.

Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting program:

Complete and submit the report online at bit.ly/3xX7Hvy.

Download form at bit.ly/3eDeSSc or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form or submit by fax to 1-800-FDA-0178.

Build your health & fitness knowledge

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.

Topics

Breaking News

News Alert